Virology
Sanger sequencing versus INNO-LiPA® HBV PreCore assay for routine detection of precore and basal core promoter mutations in hepatitis virus B chronically infected patients

https://doi.org/10.1016/j.diagmicrobio.2017.12.006Get rights and content

Highlights

  • We compared Sanger sequencing and INNO-LiPA® HBV PreCore assay.

  • A very good agreement was observed between both methods.

  • INNO-LiPA assay was a little faster, while reagent cost was lower, for sequencing.

  • The sequencing can allow the detection of additional mutations.

Abstract

We compared the Sanger sequencing and the commercial INNO-LiPA® HBV assay for the routine detection of precore (PC) and basal core promoter (BCP) mutations of hepatitis B virus in chronically infected patients. The overall agreement rate between assays was 94.2% and 98.8% for the detection of PC and BCP mutations, respectively.

Section snippets

Acknowledgments

This work was supported by the Laboratory of Virology, CHU Lille.

Transparency Declarations

No conflict of interest regarding this study.

References (18)

There are more references available in the full text version of this article.

Cited by (0)

View full text